191 related articles for article (PubMed ID: 37500122)
21. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002).
Park JY; Kim DY; Kim JH; Kim YM; Kim KR; Kim YT; Seong SJ; Kim TJ; Kim JW; Kim SM; Bae DS; Nam JH
Eur J Cancer; 2013 Mar; 49(4):868-74. PubMed ID: 23072814
[TBL] [Abstract][Full Text] [Related]
22. A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer.
McMeekin DS; Gordon A; Fowler J; Melemed A; Buller R; Burke T; Bloss J; Sabbatini P
Gynecol Oncol; 2003 Jul; 90(1):64-9. PubMed ID: 12821343
[TBL] [Abstract][Full Text] [Related]
23. Oncologic and obstetrical outcomes after fertility-preserving retreatment in patients with recurrent atypical endometrial hyperplasia and endometrial cancer.
He Y; Wang Y; Zhou R; Wang J
Int J Gynecol Cancer; 2020 Dec; 30(12):1902-1907. PubMed ID: 33051245
[TBL] [Abstract][Full Text] [Related]
24. Progestin as an alternative treatment option for multi-treated recurrent triple-negative breast cancer.
Xiangying M; Shikai W; Zefei J; Bing S; Yan M; Xin Z; Lijuan D; Yue W; Tao W; Shaohua Z; Santai S
Swiss Med Wkly; 2013; 143():w13765. PubMed ID: 23740185
[TBL] [Abstract][Full Text] [Related]
25. Administration of Cabergoline Contributes to Preserving Fertility in Young Hyperprolactinemic Patients With Endometrial Cancer Treated With Medroxyprogesterone Acetate.
Erdenebaatar C; Yamaguchi M; Saito F; Monsur M; Honda R; Tashiro H; Ohba T; Katabuchi H
Int J Gynecol Cancer; 2018 Mar; 28(3):539-544. PubMed ID: 29369118
[TBL] [Abstract][Full Text] [Related]
26. A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study.
Slomovitz BM; Filiaci VL; Walker JL; Taub MC; Finkelstein KA; Moroney JW; Fleury AC; Muller CY; Holman LL; Copeland LJ; Miller DS; Coleman RL
Gynecol Oncol; 2022 Mar; 164(3):481-491. PubMed ID: 35063278
[TBL] [Abstract][Full Text] [Related]
27. The effect of progestin therapy in advanced and recurrent endometrial cancer: A systematic review and meta-analysis.
van Weelden WJ; Birkendahl PB; Lalisang RI; IntHout J; Kruitwagen RFPM; Romano A; Pijnenborg JMA
BJOG; 2023 Jan; 130(2):143-152. PubMed ID: 36264251
[TBL] [Abstract][Full Text] [Related]
28. Aromatase inhibitor anastrozole as a second-line hormonal treatment to a recurrent low-grade endometrial stromal sarcoma: a case report.
Shoji K; Oda K; Nakagawa S; Kawana K; Yasugi T; Ikeda Y; Takazawa Y; Kozuma S; Taketani Y
Med Oncol; 2011 Sep; 28(3):771-4. PubMed ID: 20354812
[TBL] [Abstract][Full Text] [Related]
29. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer.
Chen M; Jin Y; Li Y; Bi Y; Shan Y; Pan L
Int J Gynaecol Obstet; 2016 Jan; 132(1):34-8. PubMed ID: 26493012
[TBL] [Abstract][Full Text] [Related]
30. High-dose medroxyprogesterone acetate (MPA) treatment in advanced breast cancer. A review.
Ganzina F
Tumori; 1979 Oct; 65(5):563-85. PubMed ID: 390798
[TBL] [Abstract][Full Text] [Related]
31. Does hormonal therapy for fertility preservation affect the survival of young women with early-stage endometrial cancer?
Greenwald ZR; Huang LN; Wissing MD; Franco EL; Gotlieb WH
Cancer; 2017 May; 123(9):1545-1554. PubMed ID: 28026855
[TBL] [Abstract][Full Text] [Related]
32. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study.
Muss HB; Case LD; Atkins JN; Bearden JD; Cooper MR; Cruz JM; Jackson DV; O'Rourke MA; Pavy MD; Powell BL
J Clin Oncol; 1994 Aug; 12(8):1630-8. PubMed ID: 8040675
[TBL] [Abstract][Full Text] [Related]
33. Hormone therapy for patients with advanced or recurrent endometrial cancer.
Lee WL; Yen MS; Chao KC; Yuan CC; Ng HT; Chao HT; Lee FK; Wang PH
J Chin Med Assoc; 2014 May; 77(5):221-6. PubMed ID: 24694672
[TBL] [Abstract][Full Text] [Related]
34. Systematic review of systemic therapy for advanced or recurrent endometrial cancer.
Carey MS; Gawlik C; Fung-Kee-Fung M; Chambers A; Oliver T;
Gynecol Oncol; 2006 Apr; 101(1):158-67. PubMed ID: 16434086
[TBL] [Abstract][Full Text] [Related]
35. [Two cases of multidrug-resistant recurrent endometrial cancer successfully treated with medroxyprogesterone acetate (MPA)].
Nishio S; Koyanagi T; Miyabe K; Kuromatsu H
Gan To Kagaku Ryoho; 2010 Apr; 37(4):735-8. PubMed ID: 20414038
[TBL] [Abstract][Full Text] [Related]
36. Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009.
Makker V; Hensley ML; Zhou Q; Iasonos A; Aghajanian CA
Int J Gynecol Cancer; 2013 Jun; 23(5):929-34. PubMed ID: 23598889
[TBL] [Abstract][Full Text] [Related]
37. While women await surgery for type I endometrial cancer, depot medroxyprogesterone acetate reduces tumor glandular cellularity.
Fiascone S; Danilack VA; Kao MJ; Cohen M; Singh K; Kalife E; Luis C; Lokich E; DiSilvestro P; Robison K
Am J Obstet Gynecol; 2018 Oct; 219(4):381.e1-381.e10. PubMed ID: 30063901
[TBL] [Abstract][Full Text] [Related]
38. [Conservative treatment of endometrial cancer as a way to preserve fertility. Five-year experience at Instituto Nacional de Perinatilogía Isidro Espinoza de los Reyes].
Arteaga Gómez AC; Castellanos Barroso G; Márquez Acosta G
Ginecol Obstet Mex; 2012 Jun; 80(6):394-9. PubMed ID: 22826967
[TBL] [Abstract][Full Text] [Related]
39. Fertility-Sparing Approach in Patients with Endometrioid Endometrial Cancer Grade 2 Stage IA (FIGO): A Qualitative Systematic Review.
Giampaolino P; Cafasso V; Boccia D; Ascione M; Mercorio A; Viciglione F; Palumbo M; Serafino P; Buonfantino C; De Angelis MC; Verrazzo P; Grasso G; Gullo G; Bifulco G; Della Corte L
Biomed Res Int; 2022; 2022():4070368. PubMed ID: 36203482
[TBL] [Abstract][Full Text] [Related]
40. Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer.
van Weelden WJ; Lalisang RI; Bulten J; Lindemann K; van Beekhuizen HJ; Trum H; Boll D; Werner HMJ; van Lonkhuijzen LRCW; Yigit R; Forsse D; Witteveen PO; Galaal K; van Ginkel A; Bignotti E; Weinberger V; Sweegers S; Kroep JR; Cabrera S; Snijders MPLM; Inda MA; Eriksson AGZ; ; Krakstad C; Romano A; van de Stolpe A; Pijnenborg JMA
Am J Obstet Gynecol; 2021 Oct; 225(4):407.e1-407.e16. PubMed ID: 34019887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
